Stocks TelegraphStocks Telegraph
Stock Ideas

NURPF Financial Statements and Analysis

PNK : NURPF

Neuren Pharmaceuticals

$14.00
00
At Close 4:00 PM

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateJun 30, 2025Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023
reported currencyAUDAUDAUDAUDAUD
calendar year20252024202420232023
periodQ2Q2Q1Q4Q3
revenue28.277M24.327M12.164M168.999M84.508M
cost of revenue14.897M17.889M8.945M7.831M7.831M
gross profit13.38M6.438M3.219M161.168M76.677M
gross profit ratio0.4730.2650.2650.9540.907
research and development expenses14.897M17.889M8.945M15.662M7.831M
general and administrative expenses2.483M2.374M1.187M1.644M1.644M
selling and marketing expenses000597.50K-517.50K
selling general and administrative expenses2.483M2.374M1.187M2.241M1.126M
other expenses00000
operating expenses17.38M20.263M10.132M17.903M1.42M
cost and expenses32.277M38.152M19.076M17.914M9.251M
interest income6.293M11.672M05.003M2.502M
interest expense00000
depreciation and amortization11.00K11.00K5.50K11.00K5.50K
ebitda10.908M4.075M2.038M151.096M75.557M
ebitda ratio0.3860.1680.1680.8940.894
operating income-4.00M-13.825M-6.913M151.085M75.551M
operating income ratio-0.141-0.568-0.5680.8940.894
total other income expenses net23.721M25.668M12.834M4.416M2.208M
income before tax19.721M11.843M5.922M155.501M77.759M
income before tax ratio0.6970.4870.4870.920.92
income tax expense4.69M3.827M1.914M46.225M23.121M
net income15.031M8.016M4.008M109.276M54.638M
net income ratio0.5320.330.330.6470.647
eps0.120.0310.0310.860.42
eps diluted0.120.0310.0310.830.42
weighted average shs out129.023M261.533M130.767M127.266M131.586M
weighted average shs out dil128.991M261.638M130.819M131.086M131.488M
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateJun 30, 2025Jun 30, 2024Mar 31, 2024Dec 31, 2023Jun 30, 2023
reported currencyAUDAUDAUDAUDAUD
calendar year20252024202420232023
periodQ2Q2Q1Q4Q2
cash and cash equivalents5.906M2.571M2.571M17.094M38.389M
short term investments293.631M210.602M210.602M211.445M47.286M
cash and short term investments299.537M213.173M213.173M228.539M85.675M
net receivables20.522M14.868M14.868M14.412M10.592M
inventory00000
other current assets187.00K004.205M131.00K
total current assets320.246M228.041M228.041M247.156M96.398M
property plant equipment net25.00K35.00K35.00K43.00K32.00K
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments00000
tax assets10.981M75.00K0771.00K1.093M
other non current assets0075.00K-1.000
total non current assets11.006M110.00K110.00K813.999K1.125M
other assets0001.000
total assets331.252M228.151M228.151M247.97M97.523M
account payables6.663M4.476M4.476M3.418M3.10M
short term debt00000
tax payables04.188M037.119M2.91M
deferred revenue00000
other current liabilities1.26M306.001K4.494M39.345M2.91M
total current liabilities7.923M8.97M8.97M42.763M6.01M
long term debt00000
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities55.00K29.00K29.00K00
total non current liabilities55.00K29.00K29.00K00
other liabilities00000
capital lease obligations00000
total liabilities7.978M8.999M8.999M42.763M6.01M
preferred stock01.00000
common stock127.591M175.696M175.696M173.127M169.258M
retained earnings195.462M46.404M46.404M38.388M-70.888M
accumulated other comprehensive income loss221.00K-2.948M-2.948M-6.308M-6.857M
other total stockholders equity0-1.0000-1.00
total stockholders equity323.274M219.152M219.152M205.207M91.513M
total equity323.274M219.152M219.152M205.207M91.513M
total liabilities and stockholders equity331.252M228.151M228.151M247.97M97.523M
minority interest00000
total investments293.631M210.602M210.602M211.445M47.286M
total debt00000
net debt-5.906M-2.571M-2.571M-17.094M-38.389M
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateJun 30, 2025Jun 30, 2024Mar 31, 2024Dec 31, 2023Jun 30, 2023
reported currencyAUDAUDAUDAUDAUD
calendar year20252024202420232023
periodQ2Q2Q1Q4Q2
deferred income tax00000
stock based compensation512.00K382.50K382.50K00
change in working capital155.201M1.875M1.875M26.824M-3.587M
accounts receivables155.201M1.875M1.875M00
inventory00000
accounts payables01.058M000
other working capital0-32.235M000
other non cash items-42.449M-16.539M-16.539M3.936M654.00K
net cash provided by operating activities128.306M-10.268M-10.268M140.047M44.878M
investments in property plant and equipment-5.00K-1.50K-1.50K-22.00K-18.00K
acquisitions net00000
purchases of investments-85.568M00-211.445M0
sales maturities of investments0843.00K000
other investing activites0421.50K421.50K00
net cash used for investing activites-85.573M420.00K420.00K-211.467M-18.00K
debt repayment00000
common stock issued01.651M02.522M1.097M
common stock repurchased-39.573M0000
dividends paid00000
other financing activites1.365M825.50K825.50K00
net cash used provided by financing activities-38.208M825.50K825.50K2.522M1.097M
effect of forex changes on cash-1.772M1.761M1.761M47.603M-47.748M
net change in cash2.753M-14.523M-7.262M-21.295M-1.791M
cash at end of period5.906M2.571M-7.262M17.094M38.389M
cash at beginning of period3.153M17.094M038.389M40.18M
operating cashflow128.306M-10.268M-10.268M140.047M44.878M
capital expenditure-5.00K-1.50K-1.50K-22.00K-18.00K
free cash flow128.301M-10.27M-10.27M140.025M44.86M
Graph

Frequently Asked Questions

How did Neuren Pharmaceuticals Limited do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, NURPF generated $28.28M in revenue last quarter, while its costs came in at $14.90M.
Last quarter, how much Gross Profit did Neuren Pharmaceuticals Limited report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Neuren Pharmaceuticals Limited reported a $13.38M Gross Profit for the quarter ended Jun 30, 2025.
Have NURPF's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. NURPF incurred $17.38M worth of Operating Expenses, while it generated -$4.00M worth of Operating Income.
How much Net Income has NURPF posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Neuren Pharmaceuticals Limited, the company generated $15.03M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Neuren Pharmaceuticals Limited have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Neuren Pharmaceuticals Limited as of the end of the last quarter was $5.91M.
What are NURPF's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, NURPF had Total Net Receivables of $20.52M.
In terms of Total Assets and Current Assets, where did Neuren Pharmaceuticals Limited stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of NURPF were $320.25M, while the Total Assets stand at $331.25M.
As of the last quarter, how much Total Debt did Neuren Pharmaceuticals Limited have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of NURPF's debt was $0.00 at the end of the last quarter.
What were NURPF's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, NURPF reported total liabilities of $7.98M.
How much did NURPF's Working Capital change over the last quarter?
Working Capital Change for NURPF was $155.20M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
NURPF generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. NURPF generated $128.31M of Cash from Operating Activities during its recently reported quarter.
What was NURPF's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. NURPF reported a $2.75M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph